Virological response and resistance mutations to NS3/4A inhibitors in hepatitis C virus-human immunodeficiency virus coinfection

Figure 1 Antiretroviral treatment regimens at initiation of triple anti-hepatitis C virus therapy (n = 41). PI: Protease inhibitor (atazanavir, darunavir, lopinavir, ritonavir boost); NRTI: Nucleoside analogue reverse transcriptase inhibitor (tenofovir, emtricitabine, abacavir, lamivudine); NNRTI: Non-nucleoside analogue reverse transcriptase inhibitor (efavirenz, etravirine); INSTI: Integrase strand transfer inhibitor (raltegravir).

Figure 2 Number of patients with undetectable hepatitis C virus-RNA between hepatitis C virus treatment initiation and sustained virological response 12. HCV: Hepatitis C virus; SVR: Sustained virological response.

Figure 3 Sustained virological response at 12 wk following treatment discontinuation according to prior treatment history, fibrosis severity and genotype in 40 patients with available follow-up. PTI: Premature treatment interruption; HCV: Hepatitis C virus.